JPRN-UMIN000033110招募中未知
Open labeled examination to observe the effects of the hydrogen bath for arms containing 1.6ppm molecular hydrogen on the pain and/or swelling of the hands and arms. - Open labeled examination to observe the effects of the hydrogen bath for arms containing 1.6ppm molecular hydrogen on the pain and/or swelling of the hands and arms.
Huis Ten Bosch Satellite H2 Clinic Hakata Ecomo International Co., Ltd.0 个研究点目标入组 50 人开始时间: 2018年6月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •All of the subjects do not have any infection and skin diseases.
研究者
相似试验
进行中（未招募）
不适用
An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/AEUCTR2007-004063-21-NLBiovitrum AB18
已完成
不适用
An open-label study to investigate the effects of emvododstat on the pharmacokinetics of CYP2D6 and BCRP substrates in healthy volunteersCancerNL-OMON50753PTC Therapeutics, Inc.36
已完成
不适用
An open-labeled preliminary study of the effect of Peucedanum japonicum Thunb (PJT) ingestion on serum adiponectin secretion for healthy volunteer subjectshealthy volunteer subjectsJPRN-UMIN000013683Osaka University Graduate School of Medicine45
进行中（未招募）
不适用
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AEUCTR2008-008435-29-CZWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 14.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-008435-29-FRWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50